Pan­cre­at­ic can­cer com­bo sees high sur­vival rates in Chemo­Cen­tryx PhIb da­ta

A Moun­tain View com­pa­ny is post­ing ear­ly da­ta from a pan­cre­at­ic can­cer drug pro­gram, in which its im­munother­a­py and chemother­a­py com­bo sig­nif­i­cant­ly out­per­formed chemo on its own.

The clin­i­cal-stage com­pa­ny, called Chemo­Cen­tryx $CCXI, shared pa­tient sur­vival da­ta from an 18-month Phase Ib tri­al called CCX872. Test­ing one of its CCR2 in­hibitors along­side chemother­a­py reg­i­ment Folfiri­nox, Chemo­Cen­tryx saw 29% pa­tient sur­vival at the end of the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER